• Contact
    • Imprint
    • Sitemap
      • Deutsch

UNIWUE UBWUE Universitätsbibliothek

  • Home
  • Search
  • Browse
  • Publish
  • Help
Schließen

Refine

Keywords

  • 2- deoxy-2-(18F)fluoro-D-glucose (1) (remove)

Author

  • Aulmann, Christoph (1) (remove)

Institute

  • Klinik und Poliklinik für Nuklearmedizin (1)
  • Medizinische Klinik und Poliklinik I (1)

1 search hit

  • 1 to 1
  • BibTeX
  • CSV
  • RIS
  • XML
  • 10
  • 20
  • 50
  • 100
Predictive value of \(^{18}\)F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib (2018)
Werner, Rudolf ; Schmid, Jan-Stefan ; Higuchi, Takahiro ; Javadi, Mehrbod S. ; Rowe, Steven P. ; Märkl, Bruno ; Aulmann, Christoph ; Fassnacht, Martin ; Kroiß, Matthias ; Reiners, Christoph ; Buck, Andreas ; Kreissl, Michael ; Lapa, Constantin
Introduction: Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKI). We aimed to assess the role of metabolic imaging using 2-deoxy-2-(\(^{18}\)F)fluoro-D-glucose (\(^{18}\)F-FDG) positron emission tomography/computed tomography (PET/CT) shortly before and 3 months after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline \(^{18}\)F-FDG PET/CT prior to and 3 months after TKI treatment initiation. During follow-up, CT scans were performed every 3 months and analyzed according to Response Evaluation Criteria In Solid Tumors (RECIST). The predictive value for estimating progression-free (PFS) and overall survival (OS) was examined by investigating \(^{18}\)F-FDG mean/maximum standardized uptake values (SUVmean/max) of the metabolically most active lesion as well as by analyzing clinical parameters (tumor marker doubling times {calcitonin, carcinoembryonic antigen (CEA)}, prior therapies, RET (rearranged during transfection) mutational status, and disease type). Results: Within a median follow-up of 5.2 years, 9 patients experienced disease progression after a median time interval of 2.1y whereas the remainder had ongoing disease control (n=5 partial response and n=4 stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5y after TKI initiation. Pre-therapeutic SUVmean >4.0 predicted a significantly shorter PFS (PFS: 1.9y vs. 5.2y; p=0.04). Furthermore, sustained high 18F-FDG uptake at 3 months with a SUVmean>2.8 tended to portend an unfavorable prognosis with a PFS of 1.9y (vs. 3.5y; p=0.3). Prolonged CEA doubling times were significantly correlated with longer PFS (r=0.7) and OS (r=0.76, p<0.01, respectively). None of the other clinical parameters had prognostic significance. Conclusions: Pre-therapeutic \(^{18}\)F-FDG PET/CT holds prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. Low tumor metabolism of SUVmean < 4.0 prior to treatment predicts longer progression-free survival.
  • 1 to 1

DINI-Zertifikat     OPUS4 Logo